{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T02:15:29Z","timestamp":1788315329826,"version":"build-2803163510"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T00:00:00Z","timestamp":1781740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T00:00:00Z","timestamp":1788307200000},"content-version":"vor","delay-in-days":76,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Psychiatry"],"DOI":"10.1186\/s12888-026-08271-y","type":"journal-article","created":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T17:31:09Z","timestamp":1781803869000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Impact of medication side effects on medication adherence and implications for treatment outcomes in patients with borderline personality disorder: a pilot study"],"prefix":"10.1186","volume":"26","author":[{"given":"Sarah","family":"Wazlawik","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2925-5766","authenticated-orcid":false,"given":"Claudia","family":"Oppenauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,18]]},"reference":[{"issue":"8","key":"8271_CR1","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1001\/jama.2023.0589","volume":"329","author":"F Leichsenring","year":"2023","unstructured":"Leichsenring F, Heim N, Leweke F, Spitzer C, Steinert C, Kernberg OF. Borderline personality disorder: a review. JAMA. 2023;329(8):670\u20139. https:\/\/doi.org\/10.1001\/jama.2023.0589.","journal-title":"JAMA"},{"issue":"2","key":"8271_CR2","first-page":"156","volume":"105","author":"M Mendez-Miller","year":"2022","unstructured":"Mendez-Miller M, Naccarato J, Radico JA. Borderline personality disorder. Am Fam Physician. 2022;105(2):156\u201361.","journal-title":"Am Fam Physician"},{"issue":"10310","key":"8271_CR3","doi-asserted-by":"publisher","first-page":"1528","DOI":"10.1016\/S0140-6736(21)00476-1","volume":"398","author":"M Bohus","year":"2021","unstructured":"Bohus M, Stoffers-Winterling J, Sharp C, Krause-Utz A, Schmahl C, Lieb K. Borderline personality disorder. Lancet. 2021;398(10310):1528\u201340. https:\/\/doi.org\/10.1016\/S0140-6736(21)00476-1.","journal-title":"Lancet"},{"issue":"8","key":"8271_CR4","doi-asserted-by":"publisher","first-page":"671","DOI":"10.2165\/00023210-200822080-00005","volume":"22","author":"S Bellino","year":"2008","unstructured":"Bellino S, Paradiso E, Bogetto F. Efficacy and tolerability of pharmacotherapies for borderline personality disorder. CNS Drugs. 2008;22(8):671\u201392. https:\/\/doi.org\/10.2165\/00023210-200822080-00005.","journal-title":"CNS Drugs"},{"issue":"1","key":"8271_CR5","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s40479-019-0106-3","volume":"6","author":"S Simonsen","year":"2019","unstructured":"Simonsen S, Bateman A, Bohus M, Dalewijk HJ, Doering S, Kaera A, et al. European guidelines for personality disorders: past, present and future. Borderline Personal Disord Emot Dysregulation. 2019;6(1):9. https:\/\/doi.org\/10.1186\/s40479-019-0106-3.","journal-title":"Borderline Personal Disord Emot Dysregulation"},{"issue":"3","key":"8271_CR6","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1111\/acps.12767","volume":"136","author":"A Mart\u00edn-Blanco","year":"2017","unstructured":"Mart\u00edn-Blanco A, Ancochea A, Soler J, Elices M, Carmona C, Pascual JC. Changes over the last 15 years in the psychopharmacological management of persons with borderline personality disorder. Acta Psychiatr Scand. 2017;136(3):323\u201331. https:\/\/doi.org\/10.1111\/acps.12767.","journal-title":"Acta Psychiatr Scand"},{"issue":"1","key":"8271_CR7","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1080\/14656566.2019.1686482","volume":"21","author":"P Bozzatello","year":"2020","unstructured":"Bozzatello P, Rocca P, De Rosa ML, Bellino S. Current and emerging medications for borderline personality disorder: is pharmacotherapy alone enough? Expert Opin Pharmacother. 2020;21(1):47\u201361. https:\/\/doi.org\/10.1080\/14656566.2019.1686482.","journal-title":"Expert Opin Pharmacother"},{"key":"8271_CR8","unstructured":"Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen. Fachgesellschaften (AWMF). Offizielle Leitlinien."},{"issue":"1","key":"8271_CR9","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s40479-024-00249-0","volume":"11","author":"L Mehlum","year":"2024","unstructured":"Mehlum L, Asarnow J, Neupane SP, Santamarina-Perez P, Prim\u00e9-Tous M, Carlson GA. Psychotropic medication use among adolescents participating in three randomized trials of DBT. Borderline Personal Disord Emot Dysregulation. 2024;11(1):5. https:\/\/doi.org\/10.1186\/s40479-024-00249-0.","journal-title":"Borderline Personal Disord Emot Dysregulation"},{"issue":"2","key":"8271_CR10","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1097\/HRP.0000000000000200","volume":"27","author":"SK Fineberg","year":"2019","unstructured":"Fineberg SK, Gupta S, Leavitt J. Collaborative deprescribing in borderline personality disorder: a narrative review. Harv Rev Psychiatry. 2019;27(2):75\u201386. https:\/\/doi.org\/10.1097\/HRP.0000000000000200.","journal-title":"Harv Rev Psychiatry"},{"issue":"21","key":"8271_CR11","doi-asserted-by":"publisher","first-page":"2037","DOI":"10.1056\/NEJMcp1007358","volume":"364","author":"J Gunderson","year":"2011","unstructured":"Gunderson J. Borderline personality disorder. N Engl J Med. 2011;364(21):2037\u201342. https:\/\/doi.org\/10.1056\/NEJMcp1007358.","journal-title":"N Engl J Med"},{"issue":"1","key":"8271_CR12","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1186\/s12888-019-2377-z","volume":"19","author":"C Tim\u00e4us","year":"2019","unstructured":"Tim\u00e4us C, Meiser M, Bandelow B, Engel KR, Paschke AM, Wiltfang J, et al. Pharmacotherapy of borderline personality disorder: what has changed over two decades? A retrospective evaluation of clinical practice. BMC Psychiatry. 2019;19(1):393. https:\/\/doi.org\/10.1186\/s12888-019-2377-z.","journal-title":"BMC Psychiatry"},{"issue":"1","key":"8271_CR13","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/1471-244X-12-20","volume":"12","author":"M DiBonaventura","year":"2012","unstructured":"DiBonaventura M, Gabriel S, Dupclay L, Gupta S, Kim E. A patient perspective of the impact of medication side effects on adherence: results of a cross-sectional nationwide survey of patients with schizophrenia. BMC Psychiatry. 2012;12(1):20. https:\/\/doi.org\/10.1186\/1471-244X-12-20.","journal-title":"BMC Psychiatry"},{"issue":"1","key":"8271_CR14","doi-asserted-by":"publisher","first-page":"7024275","DOI":"10.1155\/2020\/7024275","volume":"2020","author":"NR Marasine","year":"2020","unstructured":"Marasine NR, Sankhi S, Lamichhane R, Marasini NR, Dangi NB. Self-reported antidepressant drug side effects, medication adherence, and its associated factors among patients diagnosed with depression at the psychiatric hospital of Nepal. Depress Res Treat. 2020;2020(1):7024275. https:\/\/doi.org\/10.1155\/2020\/7024275.","journal-title":"Depress Res Treat"},{"key":"8271_CR15","doi-asserted-by":"publisher","first-page":"100800","DOI":"10.1016\/j.bbih.2024.100800","volume":"38","author":"F Grosso","year":"2024","unstructured":"Grosso F, Barbiani D, Cavalera C, Volpato E, Pagnini F. Risk factors associated with nocebo effects: a review of reviews. Brain Behav Immun Health. 2024;38:100800. https:\/\/doi.org\/10.1016\/j.bbih.2024.100800.","journal-title":"Brain Behav Immun Health"},{"issue":"3","key":"8271_CR16","doi-asserted-by":"publisher","first-page":"e699","DOI":"10.1097\/PR9.0000000000000699","volume":"4","author":"M Mana\u00ef","year":"2019","unstructured":"Mana\u00ef M, van Middendorp H, Veldhuijzen DS, Huizinga TWJ, Evers AWM. How to prevent, minimize, or extinguish nocebo effects in pain: a narrative review on mechanisms, predictors, and interventions. PAIN Rep. 2019;4(3):e699. https:\/\/doi.org\/10.1097\/PR9.0000000000000699.","journal-title":"PAIN Rep"},{"key":"8271_CR17","doi-asserted-by":"publisher","first-page":"1056050","DOI":"10.3389\/fpsyt.2022.1056050","volume":"13","author":"MS Mirhaj Mohammadabadi","year":"2022","unstructured":"Mirhaj Mohammadabadi MS, Mohammadsadeghi H, Eftekhar Adrebili M, Partovi Kolour Z, Kashaninasab F, Rashedi V, et al. Factors associated with pharmacological and psychotherapy treatments adherence in patients with borderline personality disorder. Front Psychiatry. 2022;13:1056050. https:\/\/doi.org\/10.3389\/fpsyt.2022.1056050.","journal-title":"Front Psychiatry"},{"issue":"3","key":"8271_CR18","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.seizure.2013.11.009","volume":"23","author":"RJA de Kinderen","year":"2014","unstructured":"de Kinderen RJA, Evers SMAA, Rinkens R, Postulart D, Vader CI, Majoie MHJM, et al. Side-effects of antiepileptic drugs: the economic burden. Seizure. 2014;23(3):184\u201390. https:\/\/doi.org\/10.1016\/j.seizure.2013.11.009.","journal-title":"Seizure"},{"issue":"2","key":"8271_CR19","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1331\/1544345053623573","volume":"45","author":"CL Cook","year":"2005","unstructured":"Cook CL, Wade WE, Martin BC, Perri M. Concordance among three self-reported measures of medication adherence and pharmacy refill records. J Am Pharm Assoc. 2005;45(2):151\u20139. https:\/\/doi.org\/10.1331\/1544345053623573.","journal-title":"J Am Pharm Assoc"},{"issue":"9","key":"8271_CR20","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1016\/S1474-4422(12)70153-9","volume":"11","author":"P Perucca","year":"2012","unstructured":"Perucca P, Gilliam FG. Adverse effects of antiepileptic drugs. Lancet Neurol. 2012;11(9):792\u2013802. https:\/\/doi.org\/10.1016\/S1474-4422(12)70153-9.","journal-title":"Lancet Neurol"},{"issue":"S1","key":"8271_CR21","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1192\/j.eurpsy.2024.575","volume":"67","author":"N Girone","year":"2024","unstructured":"Girone N, Benatti B, Cocchi M, Achilli F, Vigan\u00f2 C, Vismara M, et al. Treatment adherence across different psychiatric disorders: findings from a large patient cohort. Eur Psychiatry. 2024;67(S1):274\u20135. https:\/\/doi.org\/10.1192\/j.eurpsy.2024.575.","journal-title":"Eur Psychiatry"},{"issue":"9","key":"8271_CR22","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1111\/j.15300277.2008.00743.x","volume":"32","author":"A Zweben","year":"2008","unstructured":"Zweben A, Pettinati HM, Weiss RD, Youngblood M, Cox CE, Mattson ME, et al. Relationship between medication adherence and treatment outcomes: The COMBINE study. Alcohol Clin Exp Res. 2008;32(9):1661\u20139. https:\/\/doi.org\/10.1111\/j.15300277.2008.00743.x.","journal-title":"Alcohol Clin Exp Res"},{"issue":"1","key":"8271_CR23","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.schres.2009.05.022","volume":"113","author":"ABP Staring","year":"2009","unstructured":"Staring ABP, Mulder CL, Duivenvoorden HJ, De Haan L, Van der Gaag M. Fewer symptoms vs. more side-effects in schizophrenia? Opposing pathways between antipsychotic medication compliance and quality of life. Schizophr Res. 2009;113(1):27\u201333. https:\/\/doi.org\/10.1016\/j.schres.2009.05.022.","journal-title":"Schizophr Res"},{"key":"8271_CR24","doi-asserted-by":"publisher","first-page":"103692","DOI":"10.1016\/j.brat.2020.103692","volume":"133","author":"P Herzog","year":"2020","unstructured":"Herzog P, Feldmann M, Voderholzer U, G\u00e4rtner T, Armbrust M, Rauh E, et al. Drawing the borderline: predicting treatment outcomes in patients with borderline personality disorder. Behav Res Ther. 2020;133:103692. https:\/\/doi.org\/10.1016\/j.brat.2020.103692.","journal-title":"Behav Res Ther"},{"issue":"5","key":"8271_CR25","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/j.cpr.2012.04.004","volume":"32","author":"K Barnicot","year":"2012","unstructured":"Barnicot K, Katsakou C, Bhatti N, Savill M, Fearns N, Priebe S. Factors predicting the outcome of psychotherapy for borderline personality disorder: a systematic review. Clin Psychol Rev. 2012;32(5):400\u201312. https:\/\/doi.org\/10.1016\/j.cpr.2012.04.004.","journal-title":"Clin Psychol Rev"},{"key":"8271_CR26","doi-asserted-by":"publisher","first-page":"2135","DOI":"10.2147\/PPA.S268499","volume":"14","author":"MH Elnaem","year":"2020","unstructured":"Elnaem MH, Irwan NA, Abubakar U, Sulaiman SAS, Elrggal ME, Cheema E. Impact of medication regimen simplification on medication adherence and clinical outcomes in patients with long-term medical conditions. Patient Prefer Adherence. 2020;14:2135\u201345. https:\/\/doi.org\/10.2147\/PPA.S268499.","journal-title":"Patient Prefer Adherence"},{"issue":"4","key":"8271_CR27","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1136\/ejhpharm-2018-001725","volume":"26","author":"N Wilhelmsen","year":"2019","unstructured":"Wilhelmsen N, Eriksson T. Medication adherence interventions and outcomes: an overview of systematic reviews. Eur J Hosp Pharm. 2019;26(4):187\u201392. https:\/\/doi.org\/10.1136\/ejhpharm-2018-001725.","journal-title":"Eur J Hosp Pharm"},{"key":"8271_CR28","doi-asserted-by":"publisher","first-page":"203","DOI":"10.12775\/JEHS.2024.57.015","volume":"57","author":"A Poloczek","year":"2024","unstructured":"Poloczek A, Szczerba J. The role of pharmacotherapy and psychotherapy in borderline personality disorder - a literature review. J Educ Health Sport. 2024;57:203\u201316. https:\/\/doi.org\/10.12775\/JEHS.2024.57.015.","journal-title":"J Educ Health Sport"},{"issue":"3","key":"8271_CR29","doi-asserted-by":"publisher","first-page":"225","DOI":"10.4274\/nkmj.galenos.2024.33866","volume":"12","author":"EF Aydin","year":"2024","unstructured":"Aydin EF, Ceyhun HA, \u015eahing\u00f6z M, Okutucu FT, Kartal C. Dysfunctional personality disorder beliefs, treatment adherence and lifetime suicide attempts of bipolar disorder patients type-1. Namik Kemal Med J. 2024;12(3):225\u201334. https:\/\/doi.org\/10.4274\/nkmj.galenos.2024.33866.","journal-title":"Namik Kemal Med J"},{"issue":"8","key":"8271_CR30","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1176\/appi.ajp.2018.18050576","volume":"175","author":"J Gunderson","year":"2018","unstructured":"Gunderson J, Choi-Kain L. Medication management for patients with borderline personality disorder. Am J Psychiatry. 2018;175(8):709\u201311. https:\/\/doi.org\/10.1176\/appi.ajp.2018.18050576.","journal-title":"Am J Psychiatry"},{"issue":"1","key":"8271_CR31","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1186\/1472-6947-12-126","volume":"12","author":"B Holzner","year":"2012","unstructured":"Holzner B, Giesinger JM, Pinggera J, Zugal S, Sch\u00f6pf F, Oberguggenberger AS, et al. The computer-based health evaluation software (CHES): a software for electronic patient-reported outcome monitoring. BMC Med Inf Decis Mak. 2012;12(1):126. https:\/\/doi.org\/10.1186\/1472-6947-12-126.","journal-title":"BMC Med Inf Decis Mak"},{"issue":"1","key":"8271_CR32","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1159\/000173701","volume":"42","author":"M Bohus","year":"2009","unstructured":"Bohus M, Kleindienst N, Limberger MF, Stieglitz RD, Domsalla M, Chapman AL, et al. The short version of the Borderline Symptom List (BSL-23): development and initial data on psychometric properties. Psychopathology. 2009;42(1):32\u20139. https:\/\/doi.org\/10.1159\/000173701.","journal-title":"Psychopathology"},{"issue":"1","key":"8271_CR33","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s40479-020-00126-6","volume":"7","author":"N Kleindienst","year":"2020","unstructured":"Kleindienst N, Jungkunz M, Bohus M. A proposed severity classification of borderline symptoms using the Borderline Symptom List (BSL-23). Borderline Personal Disord Emot Dysregulation. 2020;7(1):11. https:\/\/doi.org\/10.1186\/s40479-020-00126-6.","journal-title":"Borderline Personal Disord Emot Dysregulation"},{"issue":"1","key":"8271_CR34","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.epilep.2013.01.003","volume":"1","author":"TW May","year":"2013","unstructured":"May TW. Assessment of adverse effects of antiepileptic drugs: the patient\u2019s view. Epileptology. 2013;1(1):46\u201354.","journal-title":"Epileptology"},{"issue":"7","key":"8271_CR35","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1111\/bcp.14193","volume":"86","author":"AHY Chan","year":"2020","unstructured":"Chan AHY, Horne R, Hankins M, Chisari C. The medication adherence report scale: a measurement tool for eliciting patients\u2019 reports of nonadherence. Br J Clin Pharmacol. 2020;86(7):1281\u20138.","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"8271_CR36","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1080\/08870440290001502","volume":"17","author":"R Horne","year":"2002","unstructured":"Horne R, Weinman J. Self-regulation and self-management in asthma: exploring the role of illness perceptions and treatment beliefs in explaining non-adherence to preventer medication. Psychol Health. 2002;17(1):17\u201332. https:\/\/doi.org\/10.1080\/08870440290001502.","journal-title":"Psychol Health"},{"issue":"3","key":"8271_CR37","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1093\/ibd\/izaa056","volume":"27","author":"JK Stone","year":"2021","unstructured":"Stone JK, Shafer LA, Graff LA, Lix L, Witges K, Targownik LE, et al. Utility of the MARS-5 in assessing medication adherence in IBD. Inflamm Bowel Dis. 2021;27(3):317\u201324. https:\/\/doi.org\/10.1093\/ibd\/izaa056.","journal-title":"Inflamm Bowel Dis"},{"key":"8271_CR38","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1001\/jama.282.18.1737","volume":"282","author":"RL Spitzer","year":"1999","unstructured":"Spitzer RL, Kroenke K, Williams JB. Patient health questionnaire study group. Validity and utility of a self-report version of PRIME-MD: the PHQ primary care study. JAMA. 1999;282:1737\u201344. https:\/\/doi.org\/10.1001\/jama.282.18.1737.","journal-title":"JAMA"},{"issue":"9","key":"8271_CR39","doi-asserted-by":"publisher","first-page":"509","DOI":"10.3928\/0048-5713-20020901-06","volume":"32","author":"K Kroenke","year":"2002","unstructured":"Kroenke K, Spitzer RL. The PHQ-9: a new depression diagnostic and severity measure. Psychiatr Ann. 2002;32(9):509\u201315. https:\/\/doi.org\/10.3928\/0048-5713-20020901-06.","journal-title":"Psychiatr Ann"},{"issue":"9","key":"8271_CR40","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1046\/j.1525-1497.2001.016009606.x","volume":"16","author":"K Kroenke","year":"2001","unstructured":"Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001;16(9):606\u201313. https:\/\/doi.org\/10.1046\/j.1525-1497.2001.016009606.x.","journal-title":"J Gen Intern Med"},{"issue":"10","key":"8271_CR41","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1001\/archinte.166.10.1092","volume":"166","author":"RL Spitzer","year":"2006","unstructured":"Spitzer RL, Kroenke K, Williams JB, L\u00f6we B. A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med. 2006;166(10):1092\u20137. https:\/\/doi.org\/10.1001\/archinte.166.10.1092.","journal-title":"Arch Intern Med"},{"issue":"4","key":"8271_CR42","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.genhosppsych.2010.03.006","volume":"32","author":"K Kroenke","year":"2010","unstructured":"Kroenke K, Spitzer RL, Williams JB, L\u00f6we B. The patient health questionnaire somatic, anxiety, and depressive symptom scales: a systematic review. Gen Hosp Psychiatry. 2010;32(4):345\u201357. https:\/\/doi.org\/10.1016\/j.genhosppsych.2010.03.006.","journal-title":"Gen Hosp Psychiatry"},{"key":"8271_CR43","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.genhosppsych.2015.11.005","volume":"39","author":"F Plummer","year":"2016","unstructured":"Plummer F, Manea L, Trepel D, McMillan D. Screening for anxiety disorders with the GAD-7 and GAD-2: a systematic review and diagnostic metaanalysis. Gen Hosp Psychiatry. 2016;39:24\u201331. https:\/\/doi.org\/10.1016\/j.genhosppsych.2015.11.005.","journal-title":"Gen Hosp Psychiatry"},{"key":"8271_CR44","volume-title":"Introduction to mediation, moderation, and conditional process analysis: a regression-based approach","author":"AF Hayes","year":"2022","unstructured":"Hayes AF. Introduction to mediation, moderation, and conditional process analysis: a regression-based approach. 3rd ed. New York: Guilford Press; 2022.","edition":"3"},{"issue":"4","key":"8271_CR45","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.3758\/BRM.41.4.1149","volume":"41","author":"F Faul","year":"2009","unstructured":"Faul F, Erdfelder E, Buchner A, Lang AG. Statistical power analyses using G*Power 3.1: tests for correlation and regression analyses. Behav Res Methods. 2009;41(4):1149\u201360. https:\/\/doi.org\/10.3758\/BRM.41.4.1149.","journal-title":"Behav Res Methods"},{"issue":"10","key":"8271_CR46","doi-asserted-by":"publisher","first-page":"2116","DOI":"10.1016\/j.pec.2020.04.030","volume":"103","author":"RJ Marrero","year":"2020","unstructured":"Marrero RJ, Fumero A, de Miguel A, Penate W. Psychological factors involved in psychopharmacological medication adherence in mental health patients: A systematic review. Patient Educ Couns. 2020;103(10):2116\u201331. https:\/\/doi.org\/10.1016\/j.pec.2020.04.030.","journal-title":"Patient Educ Couns"},{"key":"8271_CR47","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1111\/ppc.12483","volume":"56","author":"EE Ata","year":"2020","unstructured":"Ata EE, Bahadir-Yilmaz E, Bayrak NG. The impact of side effects on schizophrenia and bipolar disorder patients\u2019 adherence to prescribed medical therapy. Perspect Psychiatr Care. 2020;56:691\u20136. https:\/\/doi.org\/10.1111\/ppc.12483.","journal-title":"Perspect Psychiatr Care"},{"issue":"2","key":"8271_CR48","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1007\/s00213-006-0413-4","volume":"187","author":"B Janssen","year":"2006","unstructured":"Janssen B, Gaebel W, Haerter M, Komaharadi F, Lindel B, Weinmann S. Evaluation of factors influencing medication compliance in inpatient treatment of psychotic disorders. Psychopharmacology. 2006;187(2):229\u201336. https:\/\/doi.org\/10.1007\/s00213-006-0413-4.","journal-title":"Psychopharmacology"},{"key":"8271_CR49","doi-asserted-by":"publisher","first-page":"87","DOI":"10.2147\/PPA.S75013","volume":"9","author":"DG Mert","year":"2015","unstructured":"Mert DG, Turgut NH, Kelleci M, Semiz M. Perspectives on reasons of medication nonadherence in psychiatric patients. Patient Prefer Adherence. 2015;9:87\u201393. https:\/\/doi.org\/10.2147\/PPA.S75013.","journal-title":"Patient Prefer Adherence"},{"key":"8271_CR50","doi-asserted-by":"publisher","first-page":"801","DOI":"10.2147\/PPA.S125672","volume":"11","author":"OZ Rosen","year":"2017","unstructured":"Rosen OZ, Fridman R, Rosen BT, Shane R, Pevnick JM. Medication adherence as a predictor of 30-day hospital readmissions. Patient Prefer Adherence. 2017;11:801\u201310. https:\/\/doi.org\/10.2147\/PPA.S125672.","journal-title":"Patient Prefer Adherence"},{"issue":"1","key":"8271_CR51","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/s10608-018-9938-1","volume":"43","author":"LA Brown","year":"2019","unstructured":"Brown LA, Belli GM, Asnaani A, Foa EB. A review of the role of negative cognitions about oneself, others, and the world in the treatment of PTSD. Cogn Ther Res. 2019;43(1):143\u201373. https:\/\/doi.org\/10.1007\/s10608-018-9938-1.","journal-title":"Cogn Ther Res"},{"key":"8271_CR52","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s12888-019-2377-z","volume":"76","author":"B Chen","year":"2017","unstructured":"Chen B, Choi H, Hirsch LJ, Katz A, Legge A, Buchsbaum R, et al. Psychiatric and behavioral side effects of antiepileptic drugs in adults with epilepsy. Epilepsy Behav. 2017;76:24\u201331. https:\/\/doi.org\/10.1186\/s12888-019-2377-z.","journal-title":"Epilepsy Behav"},{"issue":"3","key":"8271_CR53","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1111\/j.1533-2500.2004.04304.x","volume":"4","author":"KS Walia","year":"2004","unstructured":"Walia KS, Khan EA, Ko DH, Raza SS, Khan YN. Side effects of antiepileptics\u2014A review. Pain Pract. 2004;4(3):194\u2013203. https:\/\/doi.org\/10.1111\/j.1533-2500.2004.04304.x.","journal-title":"Pain Pract"},{"issue":"2","key":"8271_CR54","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.cnur.2016.01.013","volume":"51","author":"CJ Givens","year":"2016","unstructured":"Givens CJ. Adverse drug reactions associated with antipsychotics, antidepressants, mood stabilizers, and stimulants. Nurs Clin. 2016;51(2):309\u201321. https:\/\/doi.org\/10.1016\/j.cnur.2016.01.013.","journal-title":"Nurs Clin"},{"key":"8271_CR55","doi-asserted-by":"publisher","first-page":"959","DOI":"10.4088\/jcp.v65n0712","volume":"65","author":"EM Hunkeler","year":"2004","unstructured":"Hunkeler EM, Ming E, Lee JY, Fireman B, Markson LE. Incidence and duration of side effects and those rated as bothersome with selective serotonin reuptake inhibitor treatment for depression: patient report versus physician estimate. J Clin Psychiatry. 2004;65:959\u201365. https:\/\/doi.org\/10.4088\/jcp.v65n0712.","journal-title":"J Clin Psychiatry"},{"key":"8271_CR56","doi-asserted-by":"publisher","first-page":"630206","DOI":"10.1155\/2012\/630206","volume":"2012","author":"RW Lam","year":"2012","unstructured":"Lam RW, Michalak EE, Bond DJ, Tam EM, Axler A, Yatham LN. Which depressive symptoms and medication side effects are perceived by patients as interfering most with occupational functioning? Depress Res Treat. 2012;2012:630206. https:\/\/doi.org\/10.1155\/2012\/630206.","journal-title":"Depress Res Treat"},{"issue":"2","key":"8271_CR57","doi-asserted-by":"publisher","first-page":"e00208","DOI":"10.1002\/prp2.208","volume":"4","author":"S Plan\u00e8s","year":"2016","unstructured":"Plan\u00e8s S, Villier C, Mallaret M. The nocebo effect of drugs. Pharmacol Res Perspect. 2016;4(2):e00208. https:\/\/doi.org\/10.1002\/prp2.208.","journal-title":"Pharmacol Res Perspect"},{"issue":"11","key":"8271_CR58","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1177\/070674370605101110","volume":"51","author":"AG Bulloch","year":"2006","unstructured":"Bulloch AG, Adair CE, Patten SB. Forgetfulness: a role in noncompliance with antidepressant treatment. Can J Psychiatry. 2006;51(11):719\u201322. https:\/\/doi.org\/10.1177\/070674370605101110.","journal-title":"Can J Psychiatry"},{"issue":"4","key":"8271_CR59","doi-asserted-by":"publisher","first-page":"127","DOI":"10.3200\/BMED.32.4.127-134","volume":"32","author":"TA Burra","year":"2007","unstructured":"Burra TA, Chen E, McIntyre RS, Grace SL, Blackmore ER, Stewart DE. Predictors of self-reported antidepressant adherence. Behav Med. 2007;32(4):127\u201334. https:\/\/doi.org\/10.3200\/BMED.32.4.127-134.","journal-title":"Behav Med"}],"container-title":["BMC Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12888-026-08271-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-026-08271-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-026-08271-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T01:48:08Z","timestamp":1788313688000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12888-026-08271-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,18]]},"references-count":59,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8271"],"URL":"https:\/\/doi.org\/10.1186\/s12888-026-08271-y","relation":{},"ISSN":["1471-244X"],"issn-type":[{"value":"1471-244X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,18]]},"assertion":[{"value":"8 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study retrospectively analyzed data collected within routine clinical care. All participants consented to the use of their data. The analysis was approved by the ethics commission of the Karl Landsteiner University of Health Sciences (Nr: 1045\/2024) and complies with the ethical standards of the Declaration of Helsinki.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"683"}}